193 related articles for article (PubMed ID: 31519508)
1. Amidino-Rocaglates: A Potent Class of eIF4A Inhibitors.
Chu J; Zhang W; Cencic R; Devine WG; Beglov D; Henkel T; Brown LE; Vajda S; Porco JA; Pelletier J
Cell Chem Biol; 2019 Nov; 26(11):1586-1593.e3. PubMed ID: 31519508
[TBL] [Abstract][Full Text] [Related]
2. Intercepted Retro-Nazarov Reaction: Syntheses of Amidino-Rocaglate Derivatives and Their Biological Evaluation as eIF4A Inhibitors.
Zhang W; Chu J; Cyr AM; Yueh H; Brown LE; Wang TT; Pelletier J; Porco JA
J Am Chem Soc; 2019 Aug; 141(32):12891-12900. PubMed ID: 31310112
[TBL] [Abstract][Full Text] [Related]
3. Rocaglates Induce Gain-of-Function Alterations to eIF4A and eIF4F.
Chu J; Zhang W; Cencic R; O'Connor PBF; Robert F; Devine WG; Selznick A; Henkel T; Merrick WC; Brown LE; Baranov PV; Porco JA; Pelletier J
Cell Rep; 2020 Feb; 30(8):2481-2488.e5. PubMed ID: 32101697
[TBL] [Abstract][Full Text] [Related]
4. Rocaglates convert DEAD-box protein eIF4A into a sequence-selective translational repressor.
Iwasaki S; Floor SN; Ingolia NT
Nature; 2016 Jun; 534(7608):558-61. PubMed ID: 27309803
[TBL] [Abstract][Full Text] [Related]
5. Broad anti-pathogen potential of DEAD box RNA helicase eIF4A-targeting rocaglates.
Obermann W; Azri MFD; Konopka L; Schmidt N; Magari F; Sherman J; Silva LMR; Hermosilla C; Ludewig AH; Houhou H; Haeberlein S; Luo MY; Häcker I; Schetelig MF; Grevelding CG; Schroeder FC; Lau GSK; Taubert A; Rodriguez A; Heine A; Yeo TC; Grünweller A; Taroncher-Oldenburg G
Sci Rep; 2023 Jun; 13(1):9297. PubMed ID: 37291191
[TBL] [Abstract][Full Text] [Related]
6. A comparative study of small molecules targeting eIF4A.
Naineni SK; Itoua Maïga R; Cencic R; Putnam AA; Amador LA; Rodriguez AD; Jankowsky E; Pelletier J
RNA; 2020 May; 26(5):541-549. PubMed ID: 32014999
[TBL] [Abstract][Full Text] [Related]
7. CRISPR-Mediated Drug-Target Validation Reveals Selective Pharmacological Inhibition of the RNA Helicase, eIF4A.
Chu J; Galicia-Vázquez G; Cencic R; Mills JR; Katigbak A; Porco JA; Pelletier J
Cell Rep; 2016 Jun; 15(11):2340-7. PubMed ID: 27239032
[TBL] [Abstract][Full Text] [Related]
8. Selective targeting of the DEAD-box RNA helicase eukaryotic initiation factor (eIF) 4A by natural products.
Shen L; Pelletier J
Nat Prod Rep; 2020 May; 37(5):609-616. PubMed ID: 31782447
[TBL] [Abstract][Full Text] [Related]
9. A forward genetic screen identifies modifiers of rocaglate responsiveness.
Shen L; Pugsley L; Cencic R; Wang H; Robert F; Naineni SK; Sahni A; Morin G; Zhang W; Nijnik A; Porco JA; Langlais D; Huang S; Pelletier J
Sci Rep; 2021 Sep; 11(1):18516. PubMed ID: 34531456
[TBL] [Abstract][Full Text] [Related]
10. Comparison of broad-spectrum antiviral activities of the synthetic rocaglate CR-31-B (-) and the eIF4A-inhibitor Silvestrol.
Müller C; Obermann W; Schulte FW; Lange-Grünweller K; Oestereich L; Elgner F; Glitscher M; Hildt E; Singh K; Wendel HG; Hartmann RK; Ziebuhr J; Grünweller A
Antiviral Res; 2020 Mar; 175():104706. PubMed ID: 31931103
[TBL] [Abstract][Full Text] [Related]
11. The Translation Inhibitor Rocaglamide Targets a Bimolecular Cavity between eIF4A and Polypurine RNA.
Iwasaki S; Iwasaki W; Takahashi M; Sakamoto A; Watanabe C; Shichino Y; Floor SN; Fujiwara K; Mito M; Dodo K; Sodeoka M; Imataka H; Honma T; Fukuzawa K; Ito T; Ingolia NT
Mol Cell; 2019 Feb; 73(4):738-748.e9. PubMed ID: 30595437
[TBL] [Abstract][Full Text] [Related]
12. The rocaglate CR-31-B (-) inhibits SARS-CoV-2 replication at non-cytotoxic, low nanomolar concentrations in vitro and ex vivo.
Müller C; Obermann W; Karl N; Wendel HG; Taroncher-Oldenburg G; Pleschka S; Hartmann RK; Grünweller A; Ziebuhr J
Antiviral Res; 2021 Feb; 186():105012. PubMed ID: 33422611
[TBL] [Abstract][Full Text] [Related]
13. Translation Inhibition by Rocaglates Is Independent of eIF4E Phosphorylation Status.
Chu J; Cencic R; Wang W; Porco JA; Pelletier J
Mol Cancer Ther; 2016 Jan; 15(1):136-41. PubMed ID: 26586722
[TBL] [Abstract][Full Text] [Related]
14. Exploring the targeting spectrum of rocaglates among eIF4A homologs.
Naineni SK; Cencic R; Robert F; Brown LE; Haque M; Scott-Talib J; Sénéchal P; Schmeing TM; Porco JA; Pelletier J
RNA; 2023 Jun; 29(6):826-835. PubMed ID: 36882295
[TBL] [Abstract][Full Text] [Related]
15. Strategic Diastereoselective C1 Functionalization in the Aza-Rocaglamide Scaffold toward Natural Product-Inspired eIF4A Inhibitors.
Nilewski C; Michels TD; Xiang AX; Packard GK; Sprengeler PA; Eam B; Fish S; Thompson PA; Wegerski CJ; Ernst JT; Reich SH
Org Lett; 2020 Aug; 22(16):6257-6261. PubMed ID: 32806219
[TBL] [Abstract][Full Text] [Related]
16. Stimulation of mammalian translation initiation factor eIF4A activity by a small molecule inhibitor of eukaryotic translation.
Bordeleau ME; Matthews J; Wojnar JM; Lindqvist L; Novac O; Jankowsky E; Sonenberg N; Northcote P; Teesdale-Spittle P; Pelletier J
Proc Natl Acad Sci U S A; 2005 Jul; 102(30):10460-5. PubMed ID: 16030146
[TBL] [Abstract][Full Text] [Related]
17. Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase.
Ernst JT; Thompson PA; Nilewski C; Sprengeler PA; Sperry S; Packard G; Michels T; Xiang A; Tran C; Wegerski CJ; Eam B; Young NP; Fish S; Chen J; Howard H; Staunton J; Molter J; Clarine J; Nevarez A; Chiang GG; Appleman JR; Webster KR; Reich SH
J Med Chem; 2020 Jun; 63(11):5879-5955. PubMed ID: 32470302
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model.
Bordeleau ME; Robert F; Gerard B; Lindqvist L; Chen SM; Wendel HG; Brem B; Greger H; Lowe SW; Porco JA; Pelletier J
J Clin Invest; 2008 Jul; 118(7):2651-60. PubMed ID: 18551192
[TBL] [Abstract][Full Text] [Related]
19. Inhibiting CARD11 translation during BCR activation by targeting the eIF4A RNA helicase.
Steinhardt JJ; Peroutka RJ; Mazan-Mamczarz K; Chen Q; Houng S; Robles C; Barth RN; DuBose J; Bruns B; Tesoriero R; Stein D; Fang R; Hanna N; Pasley J; Rodriguez C; Kligman MD; Bradley M; Rabin J; Shackelford S; Dai B; Landon AL; Scalea T; Livak F; Gartenhaus RB
Blood; 2014 Dec; 124(25):3758-67. PubMed ID: 25320244
[TBL] [Abstract][Full Text] [Related]
20. 1-Aminomethyl SAR in a novel series of flavagline-inspired eIF4A inhibitors: Effects of amine substitution on cell potency and in vitro PK properties.
Nilewski C; Michels TD; Packard GK; Xiang AX; Sprengeler PA; Eam B; Fish S; Thompson PA; Wegerski CJ; Nevarez A; Clarine J; Sperry S; Ernst JT; Reich SH
Bioorg Med Chem Lett; 2021 Sep; 47():128111. PubMed ID: 34353608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]